Global Azacitidine Market – Industry Trends and Forecast to 2030

Global Azacitidine Market, By Type (99.5%,

Azacitidine Market Analysis and Size

Azacitidine is a class of medications known as demethylation. The rise in the number of people suffering from chronic diseases such as breast cancer and melanoma globally acts as one of the primary factors boosting the growth of azacitidine market. The increased recommendations by several medical professionals have grown too fast and do not work properly. The development of several new drugs by major market players further influences the market.

Data Bridge Market Research analyses that the azacitidine market is expected to reach USD 142.41 million by 2030, which is USD 77.51 million in 2022, and is expected to undergo a CAGR of 7.9% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Azacitidine Market Scope and Segmentation

Market Definition

Azacitidine is the type of chemotherapy drug used to treat a group of blood or bone marrow disorders where the bone marrow fails to produce enough healthy blood cells. Several Individuals are suffering from MDS, and generally face complications such as anemia, infections, and easy bleeding or bruising. Azacitidine comes in the powder form to be mixed with water and injected subcutaneously or intravenously in a medical office or hospital outpatient department. It is generally injected once a day for 7 days.

Azacitidine Market Dynamics

Drivers

• Growing regulatory approval of drugs

Growing regulatory approval for the drugs that are used in the treatment of MDS treatment is projected to boost the market growth during the forecast period. For instance, Lupin received the U.S. FDA approval in November 2018 for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is specified for treating patients with myelodysplastic syndromes (MDS). Furthermore, the U.S. FDA approved Inqovi tablets in July 2020 for treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This signifies an important advancement in treatment options for patients suffering from myelodysplastic syndrome (MDS) who previously used to receive intravenous therapy.

Opportunities

• Increasing Cancers of Cancer

Acute myeloid leukemia (AML) is often difficult to treat, particularly for older adults and those who don't respond well to standard chemotherapy treatment options. Multiple myeloma (MM) is also a type of cancer that is treated with azacitidine by slowing down the production of these abnormal white blood cells. This factor is boosting the market growth.   

• Rising Awareness about the myelodysplastic syndrome (MDS) disease

Several government organizations and drug manufacturing companies are primarily focusing on spreading awareness about the myelodysplastic syndrome disease by providing funding for R&D of drugs which are used in the treatment of MDS and showing awareness programs about the disease. For instance, Grupo Biotoscana in October 2018, conducted a campaign to celebrate Myelodysplastic Syndrome World Awareness Day, on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease.

Restraints/Challenges

• Late Approvals from Organizations

There are numerous companies that cannot manufacture a drug unless the patent of a drug termintates. Thus, there are many chances that make the billion dollar drugs lose patents. This impedes the market growth.

This azacitidine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the azacitidine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Azacitidine Market Scope

The azacitidine market is segmented on the basis of type, product, application, route of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 99.5%
• <99.5%

Product

• Vidaza
• Generic Vidaza

Application

• Refractory anemia (RA)
• Refractory anemia with excess blasts (RAEB)
• Chronic Myelomonocytic leukemia (CMMoL)
• Others

Route of Administration

• Injectable
• Oral
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Azacitidine Market Regional Analysis/Insights

The azacitidine market is analyzed and market size insights and trends are provided by type, product, application, route of administration, distribution channel and end user as referenced above.

The major countries covered in the azacitidine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market because of the increasing healthcare expenditures and well-established healthcare infrastructure.

Asia-Pacific is considered to have the most lucrative period because of the increased consumption demand for active pharmaceutical ingredients.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Azacitidine Market Share Analysis

The azacitidine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to azacitidine market.

Key players operating in the azacitidine market include:

• Novartis AG (Switzerland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bausch Health Companies Inc. (Canada)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• H. Lundbeck A/S (Denmark)
• Takeda Pharmaceutical Company Limited (Japan)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Eisai Co., Ltd (Japan)
• Merz Pharma (Germany)